146 related articles for article (PubMed ID: 10374333)
61. [Detection of MDM2 gene amplification by fluorescence in situ hybridization and its diagnostic value in low-grade osteosarcoma].
Li L; Zhang M; Dong RF; Su YB; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):237-242. PubMed ID: 38433050
[No Abstract] [Full Text] [Related]
62. [Murine Doube Minute 2 oncogene inhibited apoptosis induced by retroviral-mediated wild-type p53].
Guo H; Liu T; Gao J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Dec; 20(6):401-6. PubMed ID: 11717930
[TBL] [Abstract][Full Text] [Related]
63. Mtbp haploinsufficiency in mice increases tumor metastasis.
Iwakuma T; Tochigi Y; Van Pelt CS; Caldwell LC; Terzian T; Parant JM; Chau GP; Koch JG; Eischen CM; Lozano G
Oncogene; 2008 Mar; 27(13):1813-20. PubMed ID: 17906694
[TBL] [Abstract][Full Text] [Related]
64. Monoallelic deletion of the p53 gene through chromosomal translocation in a small cell osteosarcoma.
Nishio J; Gentry JD; Neff JR; Nelson M; Daniels W; Perry D; Gatalica Z; Bridge JA
Virchows Arch; 2006 Jun; 448(6):852-6. PubMed ID: 16596382
[TBL] [Abstract][Full Text] [Related]
65. Analysis of 12q13-15 genes in parosteal osteosarcoma.
Gamberi G; Ragazzini P; Benassi MS; Ferrari C; Sollazzo MR; Molendini L; Merli M; Magagnoli G; Ruggieri P; Balladelli A; Orlando C; Bacchini P; Pazzagli M; Picci P
Clin Orthop Relat Res; 2000 Aug; (377):195-204. PubMed ID: 10943202
[TBL] [Abstract][Full Text] [Related]
66. Overexpression of mdm2 and p53 and association with progesterone receptor expression in benign meningiomas.
Das A; Tan WL; Teo J; Smith DR
Neuropathology; 2002 Sep; 22(3):194-9. PubMed ID: 12416559
[TBL] [Abstract][Full Text] [Related]
67. The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma.
Amary MF; Berisha F; Mozela R; Gibbons R; Guttridge A; O'Donnell P; Baumhoer D; Tirabosco R; Flanagan AM
Histopathology; 2016 Jul; 69(1):121-7. PubMed ID: 26844533
[TBL] [Abstract][Full Text] [Related]
68. Results of hyperamplification of centrosomes in naturally developing tumors of dogs.
Setoguchi A; Okuda M; Nishida E; Yazawa M; Ishizaka T; Hong SH; Hisasue M; Nishimura R; Sasaki N; Yoshikawa Y; Masuda K; Ohno K; Tsujimoto H
Am J Vet Res; 2001 Jul; 62(7):1134-41. PubMed ID: 11453492
[TBL] [Abstract][Full Text] [Related]
69. Analysis of SAS gene and CDK4 and MDM2 proteins in low-grade osteosarcoma.
Ragazzini P; Gamberi G; Benassi MS; Orlando C; Sestini R; Ferrari C; Molendini L; Sollazzo MR; Merli M; Magagnoli G; Bertoni F; Bohling T; Pazzagli M; Picci P
Cancer Detect Prev; 1999; 23(2):129-36. PubMed ID: 10101594
[TBL] [Abstract][Full Text] [Related]
70. Gnathic giant-cell-rich conventional osteosarcoma with MDM2 and CDK4 gene amplification.
Hirose K; Okura M; Sato S; Murakami S; Ikeda JI; Noda Y; Fukuda Y; Morii E; Toyosawa S
Histopathology; 2017 Jun; 70(7):1171-1173. PubMed ID: 27926798
[No Abstract] [Full Text] [Related]
71. Efficient growth inhibition of human osteosarcoma cells using a peptide derived from the MDM-2-binding site of p53.
Ito R; Kanno H; Takahashi A; Matsumoto R; Kobayashi N; Yoshida T; Saito T
Protein Pept Lett; 2010 May; 17(5):610-5. PubMed ID: 20015022
[TBL] [Abstract][Full Text] [Related]
72. Recurrent H3.3 alterations in childhood tumors.
Lindroth AM; Plass C
Nat Genet; 2013 Dec; 45(12):1413-4. PubMed ID: 24270444
[TBL] [Abstract][Full Text] [Related]
73. The Utility of MDM2 and CDK4 Immunohistochemistry and MDM2 FISH in Craniofacial Osteosarcoma.
Limbach AL; Lingen MW; McElherne J; Mashek H; Fitzpatrick C; Hyjek E; Mostofi R; Cipriani NA
Head Neck Pathol; 2020 Dec; 14(4):889-898. PubMed ID: 32026294
[TBL] [Abstract][Full Text] [Related]
74. MET overexpression turns human primary osteoblasts into osteosarcomas.
Patanè S; Avnet S; Coltella N; Costa B; Sponza S; Olivero M; Vigna E; Naldini L; Baldini N; Ferracini R; Corso S; Giordano S; Comoglio PM; Di Renzo MF
Cancer Res; 2006 May; 66(9):4750-7. PubMed ID: 16651428
[TBL] [Abstract][Full Text] [Related]
75. Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone.
Ueda Y; Dockhorn-Dworniczak B; Blasius S; Mellin W; Wuisman P; Böcker W; Roessner A
J Cancer Res Clin Oncol; 1993; 119(3):172-8. PubMed ID: 8418091
[TBL] [Abstract][Full Text] [Related]
76. [Overexpression of c-erbB-2 proto-oncogene product in chondrosarcomas].
Li N; Shen LH; Zhu QF
Zhonghua Bing Li Xue Za Zhi; 1994 Feb; 23(1):37-9. PubMed ID: 7913884
[TBL] [Abstract][Full Text] [Related]
77. Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma.
Serra M; Maurici D; Scotlandi K; Barbanti-Brodano G; Manara MC; Benini S; Picci P; Bertoni F; Bacci G; Sottili S; Baldini N
Int J Oncol; 1999 Feb; 14(2):301-7. PubMed ID: 9917506
[TBL] [Abstract][Full Text] [Related]
78. Altered p53 is associated with aggressive behavior of chondrosarcoma: a long term follow-up study.
Oshiro Y; Chaturvedi V; Hayden D; Nazeer T; Johnson M; Johnston DA; Ordóñez NG; Ayala AG; Czerniak B
Cancer; 1998 Dec; 83(11):2324-34. PubMed ID: 9840532
[TBL] [Abstract][Full Text] [Related]
79. Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40.
Daugaard S; Christensen LH; Høgdall E
APMIS; 2009 Jul; 117(7):518-25. PubMed ID: 19594492
[TBL] [Abstract][Full Text] [Related]
80. Splicing patterns of type XI collagen transcripts act as molecular markers for osteochondrogenic tumors.
Matsui Y; Kimura T; Tsumaki N; Nakata K; Yasui N; Araki N; Hashimoto N; Uchida A; Ochi T
Cancer Lett; 1998 Feb; 124(2):143-8. PubMed ID: 9500203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
